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Rational Design, Synthesis and 
Biological Evaluation of Pyrimidine-
4,6-diamine derivatives as Type-II 
inhibitors of FLT3 Selective Against 
c-KIT
Jaideep B. Bharate1, Nicholas McConnell1,2, Gunaganti Naresh1, Lingtian Zhang1,  
Naga Rajiv Lakkaniga1, Lucky Ding3, Neil P. Shah3,4, Brendan Frett1 & Hong-yu Li1
FMS-like Tyrosine Kinase 3 (FLT3) is a clinically validated target for acute myeloid leukemia (AML). 
Inhibitors targeting FLT3 have been evaluated in clinical studies and have exhibited potential to treat 
FLT3-driven AML. A frequent, clinical limitation is FLT3 selectivity, as concomitant inhibition of FLT3 
and c-KIT is thought to cause dose-limiting myelosuppression. Through a rational design approach, 
novel FLT3 inhibitors were synthesized employing a pyridine/pyrimidine warhead. The most potent 
compound identified from the studies is compound 13a, which exhibited an IC50 value of 13.9 ± 6.5 nM 
against the FLT3 kinase with high selectivity over c-KIT. Mechanism of action studies suggested that 
13a is a Type-II kinase inhibitor, which was also supported through computer aided drug discovery 
(CADD) efforts. Cell-based assays identified that 13a was potent on a variety of FLT3-driven cell lines 
with clinical relevance. We report herein the discovery and therapeutic evaluation of 4,6-diamino 
pyrimidine-based Type-II FLT3 inhibitors, which can serve as a FLT3-selective scaffold for further clinical 
development.
FMS-like tyrosine kinase-3 (FLT3) is a member of the receptor tyrosine kinase family. It is predominantly 
expressed on hematopoietic progenitor cells but is also found in other tissues such as placenta, gonads, and brain. 
This kinase is important for hematopoiesis and the immune system. The activation of FLT3 through a mutation is 
recognized as the most common molecular abnormality in acute myeloid leukemia (AML), and these mutations 
also play a role in other hematologic malignancies1,2. The majority of AMLs and acute lymphoblastic leukemias 
(ALL) have overexpression of FLT3. Therefore, this kinase has been an attractive target for AML. The observation 
that a majority of patients treated with a potent FLT3 inhibitor who developed acquired resistance harbored 
newly detected secondary kinase domain mutations in FLT3-ITD3 definitively validating FLT3-ITD as a thera-
peutic target in human AML. In recent years, several research groups have worked on the discovery and develop-
ment of potent FLT3 inhibitors4–12. A large number of FLT3 small-molecule kinase inhibitors are under clinical 
investigation such as crenolanib (1)13–16, AC220 (quizartinib, 2)17–19 and midostaurin (3) (Fig. 1)20. On April 28, 
2017, Novartis’s midostaurin (PKC412) received FDA approval for the treatment of FLT3-ITD+ AML21–23.
Recently, through computer aided drug discovery (CADD) followed by in-vitro validation, our group has 
discovered an imidazopyridine core (example 4) as a unique heterocycle inhibiting the FLT3 kinase24. The imi-
dazopyridine 4 showed FLT3 inhibition with an IC50 value of 16 nM. Similarly, other heterocycles, such as those 
containing pyrimidine, have been reported as FLT3 kinase inhibitors. Han’s group25–27 reported thieno[2,3-d]
pyrimidines as potent FLT3 inhibitors. Literature precedence also indicated that molecules with longer structures 
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[3–4 aromatic rings connected via small linkers, e.g. quizartinib (2)] possess potent activity against the FLT3 
kinase. Therefore, we designed a series of longer compounds comprising pyrimidine as the kinase-hinge war-
head (central heterocycle shown in Fig. 2) connected to two aromatic rings (A and B) via an amine bond. We 
hypothesized these compounds to be potent inhibitors of the FLT3 kinase through CADD studies. The most 
potent pyrimidine compound identified from our study is compound 13a, which displayed inhibition of the 
FLT3 kinase at both the enzymatic and cellular levels (Fig. 2). Further, compound 13a was found to be highly 
selective for FLT3 over c-KIT. This is an important discovery as dual inhibition of c-KIT and FLT3 causes a ‘syn-
thetic lethal toxicity’ leading to myelosuppression28. Therefore, 13a represents a significant finding to produce 
second-generation FLT3 inhibitors with attenuated myelosuppression potential. In the following report, we dis-
cuss the discovery and therapeutic evaluation of 4,6-diamino pyrimidines as selective, FLT3 inhibitors.
Results
Chemistry. Two scaffolds were investigated for FLT3 inhibition, one comprising 4,6-diamino pyrimidine and 
the other containing 2,6-diamino pyridine. Synthesis of the pyrimidine series involved a direct nucleophilic sub-
stitution on commercially available 4,6-dichloropyrimidine (6) with ethyl 2-(4-aminophenyl)acetate (5a) or ethyl 
2-(4-hydroxy phenyl)acetate (5b) leading to the formation of intermediate 7. Buchwald coupling of intermediate 
7 with aromatic or aliphatic amines 8 or alcohols 9 afforded intermediates 10. LiOH-mediated saponification 
of the ester, followed by amide-bond formation with various aromatic and heteroaromatic amines 12, resulted 
in the formation of the final products 13a-aj. The overall yield for the four step synthetic scheme was ~40%. 
The synthesis of analogs 13a-ak is depicted in Fig. 3. The second scaffold, utilizing 2,6-diaminopyridine as the 
warhead (18) was also synthesized using a similar synthetic route, as depicted in Fig. 4. 4,6-Diaminopyrimidine 
urea derivatives 24a-c, wherein the benzylic -CH2- was replaced with –NH-, were also prepared to see the effect 
of limiting rotatable bonds at the kinase bridge region. Three compounds were prepared in this series, two with 
pyrazole (compounds 24a-b) and one with isoxazole (compound 24c) Fig. 5.
FLT3 inhibition. All synthesized compounds were screened for inhibition of the FLT3 kinase. The initial 
screening was performed at a single point concentration of 20 µM to determine preliminary activity. After, IC50 
Figure 1. Representative examples of FLT3 kinase inhibitors 1–3 in clinical trials.
Figure 2. Design strategy for novel FLT3 inhibitors. The basic heterocycle in blue was designed to exploit 
the hinge region, while the C-region heterocycle was designed to access the allosteric pocket. At the basic 
pharmacophore region, free rotation was engineered into the scaffold to help improve FLT3 selectivity. Design 
strategies were implemented through CADD and rational design efforts in the SAR discussion.
www.nature.com/scientificreports/
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values were determined for all active compounds. FLT3 inhibition and LE (ligand efficiency) values for the pyrim-
idine series are provided in Tables 1–3. Table 1 contains the data for the pyrimidine series of compounds 13a-13j, 
wherein the other terminal of the scaffold comprises a pyrazole ring. Table 2 contains the data for pyrimidine 
series of compounds 13k-13q, wherein the other terminal of the scaffold comprises an isoxazole ring. Table 3 con-
tains the data for pyrimidine series of compounds 13r-13ak, wherein the other terminal of the scaffold comprises 
a phenyl ring. Pyridine-based compound 18 showed inhibition of the FLT3 kinase with an IC50 value of 5719 nM.
Amongst all compounds tested, the pyrimidine series of compounds, wherein the other terminal comprises a 
pyrazole ring, exhibited promising FLT3 inhibition with IC50 values in the lower nanomolar range (Table 1). The 
most potent compound, 13a, displayed inhibition of the FLT3 kinase with an IC50 value of 13.9 nM. Interestingly, 
the urea analog (compound 24a) of compound 13a, exhibited an IC50 value of 41 nM against the FLT3 kinase. 
This suggests that free rotation at the kinase bridge region could be an important factor for potent inhibition.
Kinase selectivity. FLT3 inhibitors 13a and 13k were further studied for effects on other kinases in the 
greater kinome (Table 4). Compound 13a exhibited weak inhibition of CSF-1R, RET, and Aurora B with IC50 val-
ues of 13 µM, 4.17 µM, and 79.83% inhibition at 20.0 µM, respectively. Compound 13a displayed excellent activity 
for the activation loop mutation, FLT3D835Y, with an IC50 value of 72.5 nM. At the enzymatic level, compound 13a 
is very selective for the FLT3 kinase with >100 fold less inhibition on other closely related kinases. Importantly, 
compound 13a has >500 fold selectivity for FLT3 over c-KIT (Fig. 6). This selectivity could help reduce the 
incidence of toxicity as concomitant blockade of FLT3 and c-KIT has been shown to cause myelosuppression28. 
Interestingly, the only difference between 13a and 13k is ring C (the basic pharmacophore is depicted in Fig. 2). 
In the case of 13a, ring C is a pyrazole while in 13k it is an isoxazole. Therefore, it appears that FLT3 prefers pyra-
zole functionality at the R2 position. In another pair 13 f (IC50 = 961 nM) versus 13 l (IC50 = 567 nM), where the 
R1 substituent is 3-CF3 phenyl and ring C is either pyrazole or isoxazole, the trend of FLT3 inhibition was found 
to be opposite.
Figure 3. Synthesis of the 4,6-diaminopyrimidine series 13a-13ak. Reagents and conditions: (a) Et3N (1.25 
equiv.), ethanol, 80 °C, 12 h, 80%; (b) Pd(PPh3)4, (0.03 equiv.), Cs2CO3 (2.5 equiv.), dioxane, 110 °C 12 h, 76%; (c) 
LiOH (2.5 equiv.), 1:1 THF/Water, 100 °C, 15 min, MWI, 95%; (d) EDC (2.5 equiv.), HOAt (1.0 equiv.), DIPEA 
(1.2 equiv), DMF, RT, 12 h, 40%.
www.nature.com/scientificreports/
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Figure 4. Synthesis of the 2,6-diaminopyridine series of compound 18. Reagents and conditions: (a) Et3N 
(1.25 equiv.), ethanol, 80 °C, 12 h, 80%; (b) Pd(PPh3)4, (0.03 equiv.), Cs2CO3 (2.5 equiv.), dioxane, 110 °C, 12 h, 
76%; (c) LiOH (2.5 equiv.), 1:1 THF/water, 100 °C, 15 min, MWI, 95%; (d) EDC (2.5 equiv.), HOAt (1.0 equiv.), 
DIPEA (1.2 equiv), DMF, RT, 12 h, 40%
Figure 5. Synthesis of the 4,6-diaminopyrimidine urea series 24a-c. Reagents and conditions: (a) Et3N (1.25 
equiv.), ethanol 80 °C, 12 h, 80%; (b) Pd(PPh3)4, (0.03 equiv.), Cs2CO3 (2.5 equiv.), dioxane, 110 °C, 12 h, 76%; (c) 
TFA, DCM, RT, 2 h, 95%; (d) Et3N (1.5 equiv.), DCM, 45 °C, 5 h, 30%.
www.nature.com/scientificreports/
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Cell Based Studies. Compounds were progressed to cell-based studies to further evaluate their therapeutic 
utility. Three FLT3-driven cell line models were utilized for the studies: FLT3-driven Ba/F3 cells, Molm 14 cells 
with various FLT3 mutations, and MV4–11 AML cells. As can be seen from the data in Table 5, compound 13a 
exhibited potent inhibitory activity against Ba/F3 FLT3-ITD, Molm14 par, and MV4-11 cells. However, despite 
having in vitro inhibitory activity against the FLT3D835Y mutation, compound 13a displayed a ~10-fold reduction 
in cellular activity against the Molm14D835Y cell line. Compound 13a also displayed a ~10-fold reduction against 
the Molm14F691L cell line, which harbors a “gatekeeper” mutation. Therefore, 13a is a potent and selective inhib-
itor of FLT3-ITD but exhibits a moderate reduction in activity against FLT3-ITD harboring secondary kinase 
domain mutations in cell-based studies. Other inhibitors screened, such as compound 13d, exhibited good FLT3 
inhibition but failed to effectively inhibit FLT3-driven cellular growth. This can be attributed to the high polarity 
of 13d in which the compound has difficulty diffusing through the cellular membrane. Compound 13k exhibited 
the greatest overall potency against FLT3-driven Ba/F3 and MV4-11 cells. Based on in vitro enzymatic screening, 
this result was expected as compound 13k had very weak inhibition against the FLT3D835Y mutant kinase.
Computational Studies. To further understand ligand/receptor binding interactions, 13a, 13k, and 18 were 
computationally modeled in the FLT3 tyrosine kinase (Fig. 7). In all instances, each compound is predicted to 
bind to the FLT3 kinase in a Type-II DFG-out fashion. The R2 substituent accesses an allosteric pocket while 
the R1 substituent is oriented towards the solvent. The pyrimidine heterocycle remains in close proximity to the 
kinase hinge, forming a hydrogen-bond network. From the enzymatic screening results, compound 13a drasti-
cally out-performed compound 18. The difference in activity can be attributed to the ability to form hydrogen 
bonds at the hinge. As can be seen with compound 13a, the pyrimidine is oriented towards the hinge and forms a 
hydrogen bond network. However, compound 18 is based on a pyridine scaffold, which is predicted to face away 
from the hinge. Therefore, 18 is unable to engage in hydrogen-bond interactions at the FLT3 kinase hinge despite 
having a similar structure to that of 13a.
Employing computational modeling, FLT3 binding interactions were further studied with compound 13a 
(Fig. 8). At the hinge of FLT3, compound 13a is predicted to engage in two hydrogen bonds with CYS694. Both 
hydrogen bonds occur with the amide backbone of FLT3. Other kinase inhibitors, such as sunitinib (SUTENT®), 
also engage in two hydrogen bonds at the hinge region. These hydrogen bond networks are essential for activity 
since compound 18, a compound that cannot readily form hydrogen bonds at the hinge region, is >100 fold less 
active than 13a. At the solvent region, the methyl sulfone substituent of 13a is predicted to interact with ASN701. 
It is predicted that this interaction limits the free rotation of 4-(methylsulfonyl)phenyl and helps hold the ring 
system in place. This stabilization ensures proper hydrogen bonding at the hinge. Compound 13a is able to access 
the FLT3 allosteric pocket by forming a hydrogen bond with ASP829 from the DFG motif at the bridge region. 
This interaction stabilizes the DFG motif in the ‘out’ position and permits the pyrazole moiety of 13a to enter the 
allosteric pocket. As can be observed from the docking pose of 13a, the methylene linker is rotated relative to the 
amide bond. It is predicted that this free rotation permits tighter binding since compound 24a, the non-rotatable, 
urea analog of 13a, exhibited ~3 fold lower activity. Within the allosteric pocket, the pyrazole substituent of 13a 
Entry R1 R2 X FLT3a IC50 (nM) ± SD LE
13a -Ph(4-SO2Me) -Me NH 13.9 ± 6.5 0.28
13b -Me -Me NH 37.5 ± 13 0.35
13c N -Me NH 129.3 ± 0.9 0.26
13d N -Me NH 377 ± 20 0.24
13e -Ph(4-SO2Me) -Me O 267.6 ± 25 0.24
13f -Ph(3-CF3) -Me O 961 ± 33.7 0.22
13g -Ph(4-SO2Me) -Ph(4-F) NH 3225 ± 556 0.17
13h -Ph(4-SO2Me) -Ph(4-Me) NH 4842 ± 170 0.16
13i Morpholine -Me NH 428 ± 99 0.27
13j 1-methylpiperazine -Ph(4-Br) NH 6024 ± 122 0.18
24a -Ph(4-SO2Me) -Me NH 41 ± 6.8 0.27
24b -Me -Me NH 38.2 ± 1.5 0.37
Table 1. In-vitro inhibition of FLT3 kinase by pyrimidine series of compounds 13a-13j and urea derivative 24a-b. 
aIC50 values are expressed in nM units and are the results of three independent experiments.
www.nature.com/scientificreports/
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Entry R1 X FLT3a IC50 (nM) ± SD LE
13k -Ph(4-SO2Me) NH 63.0 ± 43 0.27
13l -Ph(3-CF3) O 567.5 ± 62 0.23
13m -Ph(3-CF3) NH 1181 ± 527 0.22
13n N NH 1033 ± 121 0.23
13o -Ph(4-Br) NH 14800 ± 248 0.19
13p Morpholine NH 395 ± 78 0.28
13q Dimethylamine O 8763 ± 127 0.24
24c -Ph(4-SO2Me) NH 29 ± 1.9 0.28
Table 2. In-vitro inhibition of FLT3 kinase by pyrimidine series of compounds 13k-q and 24c. aIC50 values are 
expressed in nM units and are the results of three independent experiments.
N
N
O
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H
O
H
N
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OMe
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13ak
N
N
X
N
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13r-13ad
N
N
X
N
H
O
Y
R1
13ae-13ai
N
N
O
N
H
O
H
N
S
N
13aj
R3
Entry R1 R2 X FLT3a IC50 (nM) ± SD LE
13r -Me -Ph(3-CF3) NH 411 ± 236 0.30
13s -Ph(4-SO2Me) -Ph(3-CF3) NH 860 ± 30 0.22
13t N -Ph(4-OCF3) NH 909 ± 95.9 0.22
13u 6–1,4-benzodioxan -Ph(4-OCF3) NH 1319 ± 257 0.21
13v -Me -Ph(4-SO2Me) NH 2119 ± 401 0.27
13w N -CH2Ph(4-F) NH 4555 ± 330 0.21
13x -Me -Ph(4-tert-butyl) O 5085 ± 75.5 0.25
13y N -Ph(4-OCF3) NH 6460 ± 251 0.19
13z -Me -Ph(4-OCF3) NH 7373 ± 333 0.23
13aa -Ph(4-SO2Me) -Ph(3-F) O 7878 ± 29 0.20
13ab N -Ph(3-CF3) NH 9167 ± 236 0.19
13ac -Ph(4-SO2Me) -Ph(3-F) NH 11707 ± 106 0.19
13ad -Me -Ph(4-F) O 12829 ± 834 0.26
13ae -Ph(4-SO2Me) -Cyclopropyl NH 5553 ± 169 0.23
13af -Ph-3-CF3 -Cyclopropyl NH 8065 ± 274 0.23
13ag 6–1,4-benzodioxan -Cyclopropyl NH 10627 ± 320 0.22
13ah 1-methyl piperazine -Cyclopropyl NH 13556 ± 102 0.25
13ai Morpholine -Cyclopropyl NH 15111 ± 168 0.25
13aj -(CH2)3CH3 4-tert-butyl-thiazole O 7577 ± 132 0.23
13ak 1-benzyl piperidine -CH2Ph(2,4-Di-OMe) O 13641 ± 494 0.16
Table 3. In-vitro inhibition of FLT3 kinase by pyrimidine series of compounds 13r-13ak. aIC50 values are 
expressed in nM units and are the results of three independent experiments.
www.nature.com/scientificreports/
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efficiently fills the region. Because the isoxazole moiety at R2, as observed with compound 13k, is ~5 fold less 
active than 13a the isoxazole is not supreme in the allosteric pocket. On the pyrazole of 13a there is a methyl, as 
well as a t-butyl, and it is hypothesized that both of these aliphatic groups are important to efficiently fill the FLT3 
allosteric pocket.
Mechanism of Inhibition. Computational modeling studies suggested that compound 13a bound to 
the DFG-out conformation of the FLT3 kinase and mechanistic inhibition studies were completed to confirm 
binding. First, compound 13a was pre-incubated with the FLT3 kinase at various time intervals. Type-II kinase 
inhibitors display a time-dependent binding interaction, where an increase in incubation causes an increase in 
compound activity. This is because the compound has to push into the allosteric pocket of the kinase, which 
causes the inhibitor to have a time dependent kon. As can be seen from the incubation studies, compound 13a had 
an increase in IC50 with an increase in pre-incubation (Fig. 9). From no incubation to a 90-minute pre-incubation, 
the IC50 value exhibited a statistically significant decrease (p < 0.05). In order for 13a to reach maximal inhibition 
of the FLT3 kinase, the compound required approximately 60 minutes of pre-incubation. This is highly suggestive 
that compound 13a is accessing the FLT3 allosteric pocket and is a Type-II kinase inhibitor because the com-
pound exhibits statistically significant, time-dependent activity. In a separate experiment, the IC50 value of 13a 
was determined at various concentrations of ATP (Fig. 9). Because 13a is hypothesized to access an allosteric 
pocket on the FLT3 kinase, the compound was expected to display non-competitive inhibition characteristics 
Figure 6. Compound 13a screened against FLT3 and c-KIT with corresponding dose-response curves. 13a was 
found >500x selective for FLT3 over c-KIT.
Cell Line
GI50 (nM)
13a 13b 13d 13k 13r 13v 13ag
Ba/F3 FLT3-ITD 131.3 158.5 / 40.5 266.4 >10000 4013
Molm14 par 24.4 186.7 / 19.8 186.7 >10000 1826
Molm14D835Y 1842 2226 / 2609 2226 >10000 /
Molm14F691L 1345 1346 / 2142 1346 >10000 /
MV4–11 9.9 80.6 2251 7.2 80.6 >10000 527
Table 5. Cell-based inhibitory activity of compounds 13a, 13b, 13d, 13k, 13r, 13v, and 13ag in FLT3-driven 
cell lines.
Kinase
aIC50 (nM) ± SD
13a 13k
FLT3 13.93 ± 6.5 63.02 ± 12
FLT3D835Y 72.52 ± 14.4 13713 ± 234
c-KIT 8,799 ± 2,083 /
CSF-1R 13,040 ± 231 60.7% at 20 µM
RET 4710 ± 342 1,664
RETV804L 62.3% at 20 µM 40.8% at 20 µM
Aurora B 79.8% at 20 µM 71.9% at 20 µM
Table 4. In-vitro selectivity of compound 13a and 13k. aIC50 values are expressed in nM units and are the results 
of three independent experiments.
www.nature.com/scientificreports/
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and should not be directly competitive with ATP. It was determined that an increase in ATP concentration did 
not cause a statistically significant increase in FLT3 IC50. Therefore, ATP is unable to relieve the FLT3 inhibition 
induced by 13a because 13a binds to the DFG-out form of the kinase, and the DFG-out conformation does not 
have affinity for ATP. Therefore, these mechanistic studies are highly suggestive that compound 13a is a Type-II, 
non-competitive inhibitor that accesses the FLT3 allosteric pocket.
FLT3 vs c-KIT selectivity. To understand the selectivity of 13a for FLT3 over c-KIT, molecular modeling 
studies were performed. It was identified that 13a does not form the correct hydrogen bonding network at the 
hinge of c-KIT. As can be seen in the FLT3 docking structure, 13a forms two hydrogen bonds at CYS694, which 
is the hinge region. However, in c-KIT, 13a is oriented away from the hinge, and is unable to form essential 
hydrogen bonds (Fig. 10). This is likely due to how 13a interacts in the allosteric region as the pyrazole moiety is 
flipped between FLT3 and c-KIT. In fact, the computational binding affinity of 13a for FLT3 was determined to 
be −14.479 kcal/mol while c-KIT was −8.895 kcal/mol. Therefore, computationally 13a is very selective for FLT3 
over c-KIT, which was also confirmed experimentally.
Discussion
Using computational studies, a series of extended compounds comprising pyrimidine as the kinase-hinge war-
head connected to two aromatic rings (A and B) via an amine bond were synthesized. Amongst synthesized 
Figure 7. Compound 13a (green), 13k (yellow), and 18 (orange) computationally modeled in the FLT3 kinase.
www.nature.com/scientificreports/
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compounds, compound 13a, displayed inhibition of the FLT3 kinase with an IC50 value of 13.9 nM. The FLT3 
inhibition results presented in Tables 1–4 are indicative of the fact that there are several key structure-activity 
relationship features. These features include: (1) The central heterocycle as pyrimidine (Tables 1–3) is favored 
over pyridine. (2) Heterocycles such as pyrazole or isoxazoles as “ring C” (Tables 1–2) are preferred over a simple 
phenyl ring (Table 3) and amongst pyrazole and oxazole, pyrazole is preferred. (3) N-methyl substitution on 
pyrazole (ring C) is preferred over other bulkier groups (Table 1). (4) The linkage of the central heterocycle with 
ring B via –NH– is preferred over –O– linkage (Tables 1–3). (5) Replacement of ring A with a single methyl does 
not have significant impact on FLT3 inhibitory activity (13a versus 13b) (Table 1). (6) The 3-atom linker between 
ring B and C can be –CH2-CO-NH– or –NH-CO-NH–, which both exhibit a similar level of activity (Tables 1–2). 
(7) It appears that the t-butyl substitution on ring C is essential for efficient interaction of the inhibitor with the 
allosteric pocket (Tables 1–3 and Figs 7–8). (8) The carbonyl group of the 3-atom linker exhibits critical hydrogen 
bonding interactions with ASP829 of the DFG motif (Fig. 8). Based on these key SAR features, compound 13a 
was determined to be the best and most potent inhibitor of FLT3.
In a cellular growth inhibition assay, compound 13a displayed excellent activity for the activation loop muta-
tion, FLT3D835Y, with an IC50 value of 72.5 nM and was found to possess >500 fold selectivity for FLT3 over c-KIT 
in in vitro kinase assays. The discrepancy between the enzymatic inhibition of FLT3D835Y and cellular inhibition 
of Molm14D835Y is likely because Molm14D835Y cells express a FLT3 double mutant29. Molm14D835Y cells contain an 
internal tandem duplication (ITD) and the D835Y point mutation in the FLT3 kinase. Kinase double mutations 
are notoriously more difficult to inhibit29,30, while the biochemical assay only contains the kinase domain with a 
single, D835Y point mutation.
Figure 8. Compound 13a computationally modeled in the FLT3 kinase.
Figure 9. FLT3 inhibition kinetics with compound 13a. Pre-incubation with 13a causes a statistically 
significant increase in FLT3 inhibition (p < 0.05). An increase in ATP concentration does not cause a statistical 
significant increase in the FLT3 IC50 value (p > 0.05). Taken together, incubation kinetics suggest 13a is non-
competitive, Type-II kinase inhibitor.
www.nature.com/scientificreports/
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In computational studies, compound 13a was found to enter the allosteric pocket, which was further con-
firmed by time-dependent enzyme kinetic studies. Compound 13a had an increase in IC50 with an increase in 
pre-incubation, which is suggesting that the compound is accessing the FLT3 allosteric pocket and is a Type-II 
kinase inhibitor. Furthermore, the selectivity of compound 13a towards FLT3 over c-KIT was studied using 
molecular modeling and was then experimentally demonstrated.
In conclusion, the rational design of a series of 4,6-diamino pyrimidnyl compounds led to the discovery of a 
potent and selective FLT3 kinase inhibitor 13a. Compound 13a achieved a FLT3 IC50 value of 13.9 nM and was 
active against FLT3-driven cell lines. 13a was also active on the FLT3D835Y mutant with an IC50 of 72.5 nM and 
displayed activity in FLT3 cell lines with GI50 between 0.009–2.0 µM. From these studies, it was determined that 
the allosteric pocket of FLT3 is more responsive to pyrazole when compared to isoxazole. Further, from compu-
tational modeling, it was identified that amino acid ASN701 can interact with 13a, which can aid in the design of 
future FLT3 inhibitors. Mechanistic inhibition studies suggested that 13a is a Type-II, non-competitive inhibitor 
that accesses the FLT3 allosteric pocket. 13a was also found to be highly selective for FLT3 over c-KIT, which can 
aid in the discovery of second-generation FLT3 inhibitors with attenuated myelosuppressive profiles. Currently, 
further modification of lead 13a is underway to enhance activity on activation loop and gatekeeper mutations.
Methods
General. All solvents were reagent grade or HPLC grade and all starting materials were obtained from com-
mercial sources and used without further purification. Purity of final compounds was assessed using a Thermo 
Finnigan LCQ Deca with Thermo Surveyor LCMS System at variable wavelengths of 254 nm and 214 nm and 
final compound purity was >95%. The HPLC mobile phase consisted of a water-methanol gradient buffered 
with 0.1% formic acid. 1H NMR spectra were recorded at 400 MHz and 13C spectra were recorded at 100 MHz, 
both completed on a Varian 400 MHz instrument (Model# 4001S41ASP). High-resolution mass spectrometry 
was completed using a Bruker 9.4 T Apex-Qh hybrid Fourier transfer ion-cyclotron resonance (FT-ICR) mass 
spectrometer. Compound activity was determined with the EZ Reader II plate reader (PerkinElmer®, Walthman, 
USA). All compounds were purified using Silica gel (0.035–0.070 mm, 60 Å) flash chromatography, unless oth-
erwise noted. Microwave assisted reactions were completed in sealed vessels using a Biotage Initiator microwave 
synthesizer.
Figure 10. Compound 13a computationally modeled in FLT3 (A) and c-KIT (B).
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Synthesis of ethyl 2-(4-(6-chloropyrimidin-4-yl)amino)phenyl)acetate (7). To the mixture of 
ethyl 4-aminophenyl acetate 5 (20 g, 111.60 mmol) and 4,6-dichloropyrimidine 6 (13.79 g, 92.56 mmol) in EtOH 
(200 mL) was added triethyl amine (17.80 g, 176.23 mmol) The reaction mixture was stirred at 80 °C for 12 h. After 
completion of reaction as indicated by TLC, the solvent was removed under reduced pressure. The crude product 
thus obtained was purified by silica gel (100–200 mesh) flash chromatography with hexanes/EtOAc (1:3) to afford 
7 as white solid (26.50 g, 81.53%); m.p. 132–134 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.82 (s, 1H), 8.42 (s, 1H), 
7.51 (d, J = 8.0 Hz, 2 H), 7.20 (d, J = 8.0 Hz, 2H), 6.74 (s, 1H), 4.04 (q, J = 8.0, 16.0 Hz, 2H), 3.58 (s, 2H), 1.14 (t, 
J = 8.0 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 171.62, 161.63, 158.89, 158.35, 137.97, 130.20, 129.80, 120.92, 
105.26, 60.66, 14.50; LC-MS (ESI): m/z 292.1309 [M + H]+.
Synthesis of ethyl 2-(4-(6-(4-methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)ace-
tate (10). The 4-(methylsulfonyl)benzenamine 8a (0.882 g, 5.5 mmol) and Cs2CO3 (2.79 g, 8.58 mmol) were 
added to the solution of compound 7 (1 g, 3.4 mmol) in dioxane (4 ml). The reaction mixture was then degassed 
with argon. After 5 minutes, Pd(PPh3)4 (0.118 g, 0.102 mmol) was added and the reaction mixture was allowed 
to stir at 110 °C for 12 h. After completion of the reaction as indicated by TLC, the solvent was removed under 
reduced pressure. The reaction was slowly basified with aqueous NaHCO3 and the obtained aqueous layer was 
extracted with ethyl acetate (100 mL × 3). The organic phase was washed with aqueous NaHCO3 (100 mL × 3) 
followed by brine (100 mL × 3) solution. The obtained organic layer was then dried over MgSO4, and solvent was 
evaporated. The crude product thus obtained was purified by silica gel (100–200 mesh) flash chromatography 
with hexanes/EtOAc (1:7) to afford 10 as a yellow solid (0.920 g, 63.01%); m.p. 188–190 °C; 1H NMR (400 MHz, 
DMSO-d6): δ 9.68 (s, 1H), 9.23 (s, 1H), 8.31 (s, 1H), 7.82 (d, J = 12.0 Hz, 2H), 7.76 (d, J = 12.0 Hz, 2H), 7.44 (d, 
J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 6.22 (s, 1H), 4.05 (q, J = 8.0, 16.0 Hz, 2H), 3.56 (s, 2H), 3.10 (s, 3H), 1.15 
(t, J = 8.0 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ 171.98, 161.09, 160.26, 158.08, 145.84, 138.96, 132.33, 
130.13, 128.81, 128.54, 120.82, 118.80, 88.25, 60.80, 44.35, 40.15, 14.44; LC-MS (ESI): m/z 427.1897 [M + H]+.
Synthesis of 2-(4-(6-(4-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)acetic acid 
(11). Compound 10 (0.500 g, 1.17 mmol) was added to THF/water (1:1, 8 mL) in a pressure reaction vessel. 
LiOH (0.084 g, 3.5 mmol) was then added and the reaction was heated to 100 °C for 5 h (or 15 min in micro-
wave). TLC confirmed the complete consumption of compound 10. Organic solvent was evaporated and the 
water solution was extracted with DCM (5 × 100 ml) and all DCM layers were discarded. Then, the reaction 
was acidified with 3 M HCl to pH ~4.0. The acidified aqueous solution was extracted (10 ml × 3) with 4:1 DCM/
IPA. All extracts were combined, dried, and condensed to yield compound 11 as a white solid (0.400 g, 85.65%); 
m.p. 124–126 °C; 1H NMR (400 MHz, DMSO-d6): δ 12.24 (s, 1H), 9.73 (s, 1H), 9.27 (s, 1H), 8.32 (s, 1H), 7.86 (d, 
J = 8.0 Hz, 2H), 7.76 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 6.24 (s, 1H), 3.49 (s, 2H), 
3.11 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 173.30, 161.18, 160.33, 158.08, 145.99, 139.00, 132.43, 130.16, 
129.32, 128.55, 120.74, 118.65, 88.34, 44.47, 25.91; LC-MS (ESI): m/z 399.1773 [M + H]+.
General procedure for synthesis of 4,6-diaminopyrimidine series of compounds 13a-13ak. The 
reaction of compound 11 (0.100 g, 0.251 mmol) or its structural analogs with 5-(tert-butyl-1-methyl-1H-pyrazol-
5-amine (12a) (0.057 g, 0.376 mmol), in presence of EDC (0.120 g, 0.625 mmol), HOAt (0.034 g, 0.249 mmol), and 
DIPEA (0.053 mL, 0.410 mmol) in DMF (2 mL) was stirred at room temperature overnight. The completion of the 
reaction was monitored by TLC. After completion of the reaction, the organic layer was evaporated. The crude 
product was purified on silica gel column (mesh 100–200) using DCM: MeOH gradient (100: 0 to 70: 30 ratio of 
DCM: MeOH) mobile phase. The desired products 13a-13ak were isolated in moderate to good yields.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)
acetamide (13a). White solid (0.054 g, 40.60%); m.p 134–136 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.02 (s, 
1H), 9.70 (s, 1H), 9.28 (s, 1H), 8.36 (s, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 8.0 Hz, 
2H), 7.28 (d, J = 8.0 Hz, 2H), 6.25 (s, 1H), 6.05 (s, 1H), 3.62 (s, 2H), 3.57 (s, 3H), 3.14 (s, 3H), 1.18 (s, 9H); 13C 
NMR (100 MHz, DMSO-d6): δ 169.58, 161.18, 160.31, 159.02, 158.09, 145.94, 139.03, 138.03, 136.71, 132.47, 
129.89, 128.56, 120.80, 118.65, 95.38, 88.33, 44.46, 41.98, 35.70, 32.21, 30.74; LC-MS (ESI): m/z 534.2037 
[M + H]+.
2-(4-(6-(Methylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)acetamide 
(13b). Yellow solid (0.045 g, 29.60%); 194–196 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.98 (s, 1H), 8.88 (s, 1H), 
8.06 (s, 1H), 7.46 (d, J = 12.0 Hz, 2H), 7.20 (d, J = 12.0 Hz, 2H), 6.77 (d, J = 4.0 Hz, 1H), 6.03 (s, 1H), 5.69 (s, 
1H), 3.58 (s, 2H), 3.55 (s, 3H), 2.71 (d, J = 8.0 Hz, 3H), 1.17 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 169.71, 
163.68, 160.56, 159.02, 157.96, 139.85, 136.72, 129.71, 128.86, 120.01, 95.43, 83.68, 41.99, 35.68, 32.21, 30.75, 
27.84; LC-MS (ESI): m/z 394.2388 [M + H]+.
2-(4-(6-(3-(Piperidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)
acetamide (13c). Sticky yellow solid (0.041 g, 30.14%); 1H NMR (400 MHz, acetone-d6): δ 9.19 (s, 1H), 8.08 (s, 
2H), 7.52 (q, J = 4.0, 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 6.51 (s, 1H), 6.06 (s, 1H), 5.84 (s, 1H), 3.67 (s, 2H), 3.58 
(s, 3H), 3.33 (t, J = 8.0 Hz, 2H), 2.58 (s, 6H), 1.84 (t, J = 8.0 Hz, 2H), 1.66 (t, J = 4.0Hz, 4H), 1.47 (t, J = 8.0 Hz, 2H), 
1.20 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 170.70, 169.70, 163.10, 159.02, 158.02, 139.82, 136.72, 129.71, 
128.90, 120.05, 95.41, 88.03, 56.63, 54.38, 42.32, 41.97, 37.55, 35.68, 32.20, 30.74, 25.81, 24.37; LC-MS (ESI): m/z 
505.2822 [M + H]+.
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2-(4-(6-(3-(Pyrrolidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)
acetamide (13d). Sticky pale yellow solid (0.039 g, 28.26%); 1H NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 8.82 
(s, 1H), 8.03 (s, 1H), 7.42 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 6.83 (s, 1H), 6.00 (s, 1H), 5.70 (s, 1H), 3.55 
(s, 2H), 3.53 (s, 3H), 3.17 (s, 2H), 2.41 (s, 6H), 1.64 (s, 6H), 1.15 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 169.68, 
163.13, 159.01, 158.02, 139.84, 136.72, 130.40, 129.71, 128.88, 120.04, 95.40, 90.18,54.02, 53.75, 45.58, 41.98, 
35.69, 32.21, 30.75, 28.62, 23.50; LC-MS (ESI): m/z 491.2592 [M + H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-yloxy)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)
acetamide (13e). Sticky yellow solid (0.042 g, 31.57%); 1H NMR (400 MHz, DMSO-d6): δ 10.07 (d, J = 4.0 Hz, 
2H), 8.43 (s, 1H), 7.87 (d, J = 8.0Hz, 2H), 7.80 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 
6.19 (s, 1H), 6.04 (s, 1H), 3.69 (s, 2H), 3.57 (s, 3H), 3.12 (s, 3H), 1.16 (s, 9H); 13C NMR (100 MHz, DMSO-d6): 
δ 169.97, 169.23, 162.40, 159.07, 158.57, 151.59, 145.05, 136.66, 133.53, 133.41, 131.11, 128.65, 121.94, 119.17, 
95.30, 90.73, 44.37, 40.55, 35.74, 32.22, 30.75; LC-MS (ESI): m/z 535.2312 [M + H]+.
2-(4-(6-(3-(Trifluoromethyl)phenylamino)pyrimidin-4-yloxy)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)
acetamide (13f). Yellow solid (0.046 g, 34.32%); m.p. 140–142 °C; 1H NMR (400 MHz, acetone-d6): δ 9.27 (s, 
1H), 9.07 (s, 1H), 8.38 (s, 1H), 8.21 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.44 (d, J = 8.0 Hz, 
2H), 7.32 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 2H), 6.17 (s, 1H), 6.11 (s, 1H), 3.77 (s, 2H), 3.60 (s, 3H), 1.21 (s, 
9H); 13C NMR (100 MHz, acetone-d6): δ 170.92, 169.63, 163.50, 160.02, 159.03, 152.82, 141.87, 137.03, 133.64, 
131.47, 131.19, 130.55, 126.65, 123.89, 122.40, 119.45, 116.64, 95.96, 90.64, 42.76, 35.65, 32.69, 30.79; LC-MS 
(ESI): m/z 525.2342 [M + H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-(4-fluorophenyl)-
1H-pyrazol-5-yl)acetamide (13g). Pale yellow solid (0.043 g, 34.95%); m.p. 168–170 °C; 1H NMR (400 MHz, 
acetone-d6): δ 8.98 (s, 1H), 8.89 (s, 1H), 8.47 (s, 1H), 8.40 (s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.83 (d, J = 8.0 Hz, 2H), 
7.54 (d, J = 8.0 Hz, 2H), 7.44–7.41 (m, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.18 (t, J = 8.0 Hz, 2H), 6.41 (s, 1H), 6.31 (s, 
1H), 3.65 (s, 2H), 3.07 (s, 3H), 1.29 (s, 9H); 13C NMR (100 MHz, acetone-d6): δ 168.81, 162.48,(d, 1JCF = 244 Hz), 
161.37, 161.27, 157.89, 145.65, 145.57, 138.97, 133.16, 129.80, 128.36, 125.88, 125.89, 120.97, 120.82, 118.53, 
118.44, 115.84, (d, 2JCF = 23 Hz), 97.33, 87.68, 43.79, 42.29, 32.06, 28.36; LC-MS (ESI): m/z 614.2142 [M + H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)
acetamide (13h). Yellow solid (0.049 g, 32.02%); m.p. 155–157 °C; 1H NMR (400 MHz, acetone-d6): δ 8.91 (s, 
1H), 8.83 (s, 1H), 8.48 (s, 1H), 8.41 (s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.83 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.0 Hz, 
2H), 7.29–7.19 (m, 6H), 6.44 (s, 1H), 6.32 (s, 1H), 3.65 (s, 2H), 3.06 (s, 3H), 2.31 (s, 3H), 1.29 (s, 9H); 13C NMR 
(100 MHz, acetone-d6): δ 168.47, 161.36, 160.97, 160.49, 157.90, 145.65, 139.03, 136.79, 136.45, 135.99, 133.16, 
129.85, 129.59, 128.36, 123.74, 120.87, 120.72, 118.53, 118.44, 96.43, 87.68, 43.79, 42.32, 32.04, 20.06; LC-MS 
(ESI): m/z 610.2609 [M + H]+.
2-(4-(6-Morpholinopyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)acetamide 
(13i). Sticky white solid (0.040 g, 28.16%); 1H NMR (400 MHz, DMSO-d6): δ 9.99 (s, 1H), 9.07 (s, 1H), 8.20 (s, 
1H), 7.52 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H), 6.04 (s, 1H), 5.94 (s, 1H), 3.66 (t, J = 4.0 Hz, 4H), 3.59 (s, 
2H), 3.56 (s, 3H), 3.43 (t, J = 4.0 Hz, 4H), 1.18 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 169.67, 162.89, 161.43, 
159.03, 157.75, 139.58, 136.72, 129.76, 129.13, 120.03, 95.42, 84.44, 66.21, 44.36, 41.99, 35.69, 32.21, 30.74; LC-MS 
(ESI): m/z 450.3030 [M + H]+.
2-(4-(6-(4-Methylpiperazin-1-yl)pyrimidin-4-ylamino)phenyl)-N-(3-tert-butyl-1-(4-bromophenyl)-1H-pyrazol-
5-yl)acetamide (13j). Colourless solid (0.056 g, 30.43%); m.p. 110–112 °C; 1H NMR (400 MHz, acetone-d6): δ 
8.95 (s, 1H), 8.21 (s, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 12.0 Hz, 2H), 7.33 (d, J = 12.0 Hz, 2H), 7.23 (d, 
J = 12.0 Hz, 2H), 6.39 (s, 1H), 6.01 (s, 1H), 3.62 (s, 2H), 3.57–3.52 (m, 4H), 2.38 (t, J = 8.0 Hz, 4H), 2.23 (s, 3H), 
1.27 (s, 9H); 13C NMR (100 MHz, acetone-d6): δ 168.83, 162.84, 161.60, 161.47, 157.55, 139.82, 138.34, 136.20, 
132.06, 129.64, 128.38, 125.20, 120.09, 119.72, 97.80, 83.91, 54.40, 45.38, 43.65, 42.40, 32.08, 27.70; LC-MS (ESI): 
m/z 605.1965 [M + H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide 
(13k). Yellow solid (0.055 g, 42.30%); m.p. 168–170 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.15 (s, 1H), 9.68 (s, 
1H), 9.26 (s, 1H), 8.34 (s, 1H), 7.86 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.25 (d, 
J = 8.0 Hz, 2H), 6.55 (s, 1H), 6.23 (s, 1H), 3.60 (s, 2H), 3.12 (s, 3H), 1.26 (s, 9H); 13C NMR (100 MHz, DMSO-d6): 
δ 180.82, 170.02, 161.14, 160.30, 158.35, 158.06, 145.91, 139.06, 132.45, 129.90, 129.58, 128.53, 120.85, 118.82, 
93.47, 88.26, 44.43, 42.32, 32.89, 28.71; LC-MS (ESI): m/z 521.1169 [M + H]+.
2-(4-(6-(3-(Trifluoromethyl)phenylamino)pyrimidin-4-yloxy)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide 
(13l). Colorless solid (0.050 g, 38.16%); m.p. 120–122 °C; 1H NMR (400 MHz, acetone-d6): δ 10.16 (s, 1H), 9.06 
(s, 1H), 8.37 (s, 1H), 8.20 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.32 (d, 
J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 2H), 6.65 (s, 1H), 6.18 (s, 1H), 3.82 (s, 2H), 1.31 (s, 9H); 13C NMR (100 MHz, 
acetone-d6): δ 180.77, 170.03, 162.61, 158.13, 158.04, 152.00, 140.98, 132.44, 130.62, 129.66, 123.01, 121.52, 
118.60, 118.56, 118.52, 116.00, 115.96, 92.95, 89.73, 42.25, 32.55, 27.93; LC-MS (ESI): m/z 512.2689 [M + H]+.
2-(4-(6-(3-(Trifluoromethyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide 
(13m). White solid (0.051 g, 38.93%); m.p 254–256 °C; 1H NMR (400 MHz, acetone-d6): δ 10.04 (s, 1H), 8.68 (s, 
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1H), 8.33 (d, J = 8.0 Hz, 2H), 8.18 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.52–7.46 (m, 3H), 7.34 (d, J = 8.0 Hz, 2H), 7.26 
(d, J = 8.0 Hz, 1H), 6.64 (s, 1H), 6.24 (s, 1H), 3.75 (s, 2H), 1.30 (s, 9H); 13C NMR (100 MHz, acetone-d6): δ 180.69, 
169.22, 161.29, 160.84, 158.07, 157.92, 141.71, 138.95, 129.73, 129.51, 122.63, 120.93, 120.78, 117.75, 117.71, 
117.67, 115.62, 92.91, 86.58, 42.41, 32.53, 27.92; LC-MS (ESI): m/z 511.1696 [M + H]+.
2-(4-(6-(3-(Pyrrolidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide 
(13n). White solid (0.049 g, 36.56%); m.p. 154–156 °C; 1H NMR (400 MHz, acetone-d6): δ 10.02 (s, 1H), 8.09 (s, 
1H), 8.04 (s, 1H), 7.54–7.51 (m, 2H), 7.31 (d, J = 8.0 Hz, 2H), 6.64 (s, 1H), 6.28 (s, 1H), 5.83 (s, 1H), 3.73 (s, 2H), 
3.33 (s, 2H), 2.53 (t, J = 8.0 Hz, 2H), 2.47 (s, 4H), 1.77 (t, J = 8.0 Hz, 2H), 1.73–1.70 (m, 4H), 1.31 (s, 9H); 13C NMR 
(100 MHz, acetone-d6): δ169.83, 169.26, 163.42, 157.88, 139.71, 130.29, 129.55, 128.69, 120.18, 120.04, 92.91, 
89.97, 53.74, 53.68, 42.42, 39.56, 37.71, 32.52, 28.92, 23.21; LC-MS (ESI): m/z 478.1989 [M + H]+.
2-(4-(6-(4-Bromophenoxy)pyrimidin-4-ylamino)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide (13o). White 
solid (0.046 g, 35.38%); m.p. 188–190 °C; 1H NMR (400 MHz, acetone-d6): δ 10.06 (s, 1H), 8.77 (s, 1H), 8.29 
(s, 1H), 7.60 (d, J = 8.0 Hz, 4H), 7.37 (d, J = 8.0 Hz, 2 H), 7.16 (d, J = 8.0 Hz, 2H), 6.65 (s, 1H), 6.22 (s, 1H), 3.77 
(s, 2H), 1.31 (s, 9H); 13C NMR (100 MHz, acetone-d6): δ; 180.68, 169.42, 163.08, 158.07, 152.52, 138.54, 132.48, 
129.98, 129.73, 129.45, 123.77, 120.63, 120.49, 117.38, 92.93, 88.88, 42.40, 32.53, 27.93; LC-MS (ESI): m/z 
522.1923 [M + H]+.
2-(4-(6-Morpholinopyrimidin-4-ylamino)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide (13p). White solid 
(0.054 g, 39.13%); m.p. 218–220 °C; 1H NMR (400 MHz, DMSO-d6): δ 11.13 (s, 1H), 9.07 (s, 1H), 8.19 (s, 1H), 
7.49 (d, J = 12.0Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 6.56 (s, 1H), 5.94 (s, 1H), 3.66 (t, J = 4.0Hz, 4H), 3.58 (s, 2H), 
3.43 (t, J = 4.0 Hz, 4H), 1.26 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 180.82, 170.11, 162.89, 161.39, 158.38, 
157.74, 139.63, 129.80, 128.79, 120.04, 93.51, 84.41, 66.20, 44.35, 42.33, 32.90, 28.74; LC-MS (ESI): m/z 437.1940 
[M + H]+.
2-(4-(6-(Dimethylamino)pyrimidin-4-yloxy)phenyl)-N-(5-tert-butylisoxazol-3-yl)acetamide (13q). Colourless 
solid (0.045 g, 31.25%); m.p. 170–172 °C; 1H NMR (400 MHz, acetone-d6): δ 10.14 (s, 1H), 8.11 (s, 1H), 7.40 (d, 
J = 8.0 Hz, 2H), 7.07 (d, J = 8.0 Hz, 2H), 6.65 (s, 1H), 5.98 (s, 1H), 3.79 (s, 2H), 3.07 (s, 6H), 1.30 (s, 9H); 13C NMR 
(100 MHz, acetone-d6): δ 180.72, 169.80, 169.09, 164.53, 158.06, 157.26, 152.50, 131.68, 130.23, 121.42, 92.95, 
85.52, 42.32, 36.36, 32.55, 27.95; LC-MS (ESI): m/z 396.2055 [M + H]+.
2-(4-(6-(Methylamino)pyrimidin-4-ylamino)phenyl)-N-(3-(trifluoromethyl)phenyl) acetamide (13r). White solid 
(0.050 g, 32.25%); m.p. 216–218 °C; 1H NMR (400 MHz, acetone-d6): δ 9.60 (s, 1H), 8.17 (s, 1H), 8.08 (s, 1H), 7.82 
(d, J = 8.0 Hz, 1H), 7.53–7.48 (m, 4H), 7.36 (d, J = 8.0Hz, 1 H), 7.29 (d, J = 8.0 Hz, 2H), 5.98 (s, 1H), 5.78 (s, 1H), 
3.67 (s, 2H), 2.82 (d, J = 4.0Hz, 3H); 13C NMR (100 MHz, acetone-d6): δ 169.78, 164.00, 157.78, 140.25, 139.62, 
129.63, 129.52, 128.97, 122.47, 122.38, 120.17, 120.03, 119.56, 119.52, 115.48, 82.71, 43.19, 27.19; LC-MS (ESI): 
m/z 402.2207 [M +H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(3-(trifluoromethyl)phenyl)acetamide 
(13 s). White solid (0.045 g, 33.33%); m.p. 225–227 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.49 (s, 1H), 9.69 
(s, 1H), 9.27 (s, 1H), 8.34 (s, 1H), 8.10 (s, 1H), 7.86 (d, J = 8.0Hz, 2H), 7.78 (d, J = 8.0Hz, 3H), 7.53 (t, J = 8.0Hz, 
1H), 7.48 (d, J = 8.0Hz, 2H), 7.38 (d, J = 8.0Hz, 1H), 7.28 (d, J = 8.0Hz, 2H), 6.23 (s, 1H), 3.62 (s, 2H), 3.12 (s, 
3H); 13C NMR (100 MHz, DMSO-d6): δ 170.38, 161.19, 160.33, 158.10, 145.95, 140.40, 139.07, 132.47, 130.43, 
129.96, 129.88, 129.70, 128.56, 123.00, 120.87, 119.93, 118.65, 115.50, 115.46, 88.30, 44.46, 43.16; LC-MS (ESI): 
m/z 542.1709 [M + H]+.
2-(4-(6-(3-(Pyrrolidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(4-(trifluoromethoxy)phenyl)acetamide 
(13t). White solid (0.044 g, 30.55%); m.p. 212–214 °C; 1H NMR (400 MHz, acetone-d6): δ 9.52 (s, 1H), 8.06 (d, 
J = 8.0Hz, 2H), 7.77 (d, J = 8.0Hz, 2H), 7.51–7.48 (m, 2H), 7.28 (d, J = 8.0Hz, 2H), 7.23 (d, J = 12.0Hz, 2H), 6.27 
(d, J = 4.0Hz, 1H), 5.80 (s, 1H), 3.64 (s, 2H), 3.31 (s, 2H), 2.50 (t, J = 8.0Hz, 2H), 2.44 (t, J = 8.0Hz, 4H), 1.74 (t, 
J = 4.0Hz, 2H), 1.70–1.67 (m, 4H); 13C NMR (100 MHz, acetone-d6): δ 169.36, 163.38, 157.86, 144.17, 139.50, 
138.58, 129.50, 121.46, 120.39, 120.30, 120.23, 120.09, 119.29, 82.98, 53.70, 53.76, 43.16, 43.11, 39.48,23.20; 
LC-MS (ESI): m/z 515.1573 [M + H]+.
2-(4-(6-(2,3-Dihydrobenzo[b][1,4]dioxin-5-ylamino)pyrimidin-4-ylamino)phenyl)-N-(4-(trifluoromethoxy)phenyl)
acetamide (13 u). White solid (0.047 g, 33.09%); m.p 275–277 °C; 1H NMR (400 MHz, acetone-d6): δ 9.69 (s, 
1H), 8.26 (s, 1H), 8.21 (s, 1H), 8.08 (s, 1H), 7.81 (d, J = 8.0Hz, 2H), 7.54–7.47 (m, 2H), 7.32 (d, J = 8.0Hz, 2H), 
7.25 (d, J = 8.0Hz, 2H), 7.18–7.16 (m, 1H), 6.93–6.89 (m, 1H), 6.76 (d, J = 8.0Hz, 1H), 6.13 (s, 1H), 4.26–4.22 
(m, 4H), 3.68 (s, 2H); 13C NMR (100 MHz, acetone-d6): δ 169.47, 161.49, 161.10, 157.95, 143.55, 139.57, 139.24, 
138.74, 133.86, 129.55, 122.23, 121.44, 120.40, 120.37, 120.31, 120.22, 116.90, 114.34, 110.32, 84.88, 64.39, 64.13, 
43.13; LC-MS (ESI): m/z 538.2409 [M +H]+.
2-(4-(6-(methylamino)pyrimidin-4-ylamino)phenyl)-N-(4-(methylsulfonyl)phenyl) acetamide (13 v). Yellow solid 
(0.044 g, 27.67%); m.p. 220–222 °C; 1H NMR (400 MHz, acetone-d6): δ 9.79 (s, 1H), 8.16 (s, 1H), 8.08 (s, 1H), 7.89 
(d, J = 8.0Hz, 2H), 7.84 (d, J = 8.0Hz, 2H), 7.51 (d, J = 8.0Hz, 2H), 7.29 (d, J = 8.0Hz, 2H), 6.05 (d, J = 8.0Hz, 1H), 
5.78 (s, 1H), 3.69 (s, 2H), 3.05 (s, 3H), 2.82 (d, J = 4.0Hz, 3H); 13C NMR (100 MHz, acetone-d6): δ 170.04, 163.99, 
157.77, 144.00, 139.61, 135.33, 129.57, 128.89, 128.35, 120.25, 118.96, 118.88, 82.63, 43.65, 43.18, 27.23; LC-MS 
(ESI): m/z 412.1931 [M +H]+.
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N-(4-Fluorobenzyl)-2-(4-(6-(3-(pyrrolidin-1-yl)propylamino)pyrimidin-4-yloxy)phenyl)acetamide (13w). Sticky 
colourless solid (0.042 g, 32.30%); 1H NMR (400 MHz, DMSO-d6): δ 8.80 (s, 1H), 8.47 (t, J = 8.0Hz, 1H), 8.03 
(s, 1H), 7.38 (d, J = 8.0Hz, 1H), 7.24 (dd, J = 4.0, 8.0Hz, 2H), 7.13–7.07 (m, 4H), 6.85 (t, J = 8.0Hz, 1H), 5.71 
(s, 1H), 4.20 (d, J = 4.0Hz, 2H), 3.36 (s, 2H), 3.18 (s, 3H), 2.54 (s, 5H), 1.68–1.64 (m, 6H); 13C NMR (100 MHz, 
DMSO-d6): δ 170.40, 162.66, (d, 1JCF = 241Hz), 159.90, 157.59, 139.12, 135.72, 129.28, 129.20,129.19, 129.10, 
119.64, 115.06, (d, 2JCF = 21Hz), 83.66, 53.50, 53.06, 41.71, 41.46, 38.53, 27.69, 22.98; LC-MS (ESI): m/z 464.1752 
[M + H]+.
2-(4-(6-(Methylamino)pyrimidin-4-yloxy)phenyl)-N-(4-tert-butylphenyl)acetamide (13x). White solid (0.046 g, 
30.66%); m.p. 208–210 °C; 1H NMR (400 MHz, DMSO-d6): δ 10.12 (s, 1H), 7.62 (t, J = 8.0Hz, 2H), 7.56–7.51 (m, 
3H), 7.37 (d, J = 8.0Hz, 2H), 7.31 (d, J = 12.0Hz, 3H), 7.08 (d, J = 8.0Hz, 2H), 3.63 (s, 2H), 2.76 (s, 3H), 1.24 (s, 
9H); 13C NMR (100 MHz, DMSO-d6): δ 169.25, 151.95, 145.97, 137.04, 132.47, 131.95, 130.73, 129.24, 129.12, 
125.73, 121.77, 119.30, 85.70, 43.01, 42.12, 34.41, 31.61; LC-MS (ESI): m/z 391.2869 [M +H]+.
2-(4-(6-(3-(Piperidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(4-(trifluoromethoxy)phenyl)acetamide 
(13y). Sticky pale yellow solid (0.041 g, 28.67%); 1H NMR (400 MHz, DMSO-d6): δ 10.40 (s, 1H), 8.89 (s, 1H), 
8.06 (s, 1H), 7.69 (d, J = 8.0Hz, 2H), 7.40 (d, J = 8.0Hz, 2H), 7.27 (d, J = 8.0Hz, 2H), 7.20 (d, J = 8.0Hz, 2H), 
6.97 (s, 1H), 5.75 (s, 1H), 3.55 (s, 2H), 2.95 (s, 5H), 1.85 (s, 3H), 1.69 (s, 5H), 1.49 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ 170.09, 162.99, 160.48, 158.03, 143.86, 139.62, 138.89, 129.78, 129.32, 122.03, 120.80, 120.30, 119.27, 
83.97, 54.45, 52.59, 43.05, 31.12, 24.26, 23.13, 21.92; LC-MS (ESI): m/z 529.1870 [M + H]+.
2-(4-(6-(Methylamino)pyrimidin-4-ylamino)phenyl)-N-(4-(trifluoromethoxy)phenyl) acetamide (13z). White 
solid (0.052 g, 32.29%); m.p 220–222 °C; 1H NMR (400 MHz, acetone-d6): δ 9.47 (s, 1H), 8.08 (s, 2H), 7.76 (d, 
J = 8.0Hz, 2H), 7.51 (d, J = 8.0Hz, 2H), 7.25 (q, J = 8.0Hz, 4H), 5.99 (s, 1H), 5.78 (s, 1H), 3.64 (s, 2H), 2.82 (d, 
J = 4.0Hz, 3H); 13C NMR (100 MHz, acetone-d6): δ 169.41, 164.01, 157.79, 144.18, 139.58, 138.65, 129.49, 129.14, 
121.47, 120.38, 120.29, 120.18, 120.04, 82.71, 43.16, 27.19; LC-MS (ESI): m/z 418.2319 [M + H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-yloxy)phenyl)-N-(3-f luorophenyl)acetamide 
(13aa). Brown solid (0.038 g, 30.89%); m.p. 228–230 °C; 1H NMR (400 MHz, acetone-d6): δ 9.67 (s, 1H), 9.29 
(s, 1H), 8.40 (s, 1H), 7.97 (d, J = 8.0Hz, 2H), 7.84 (d, J = 8.0Hz, 2H), 7.70 (d, J = 12.0Hz, 1H), 7.45 (d, J = 8.0Hz, 
2H), 7.34–7.27 (m, 2H), 7.13 (d, J = 8.0Hz, 2H), 6.80 (t, J = 8.0Hz, 1H), 6.24 (s, 1H), 3.75 (s, 2H), 3.06 (s, 3H), 13C 
NMR (100 MHz, acetone-d6): δ 170.13, 169.25, 169.16, 163.99 (d, 1JCF = 240Hz), 162.35, 158.09, 151.84, 144.93, 
144.84, 132.91, 130.61, 130.16 (d, 3JCF = 9.0Hz), 128.39, 121.47, 118.95, 114.72, 109.78, (d, 2JCF = 22Hz), 106.28, 
(d, 2JCF = 26Hz), 90.52, 43.73, 42.98; LC-MS (ESI): m/z 493.1870 [M +H]+.
2-(4-(6-(3-(Pyrrolidin-1-yl)propylamino)pyrimidin-4-ylamino)phenyl)-N-(3-(trifluoromethyl)phenyl)acetamide 
(13ab). Sticky pale yellow solid (0.045 g, 32.14%); 1H NMR (400 MHz, DMSO-d6): δ 10.51 (s, 1H), 8.84 (s, 1H), 
8.08 (s, 1H), 8.03 (s, 1H), 7.76 (d, J = 8.0Hz, 1H), 7.51 (t, J = 8.0Hz, 1H), 7.41 (d, J = 8.0Hz, 2H), 7.35 (d, J = 8.0Hz, 
1H), 7.20 (d, J = 8.0Hz, 2H), 6.85 (s, 1H), 5.72 (s, 1H), 3.57 (s, 2H), 3.18 (s, 2H), 2.54 (s, 6H), 1.64–1.59 (m, 6H); 
13C NMR (100 MHz, DMSO-d6): δ 167.16, 159.79, 154.71, 137.13, 136.51, 127.08, 126.67, 126.47, 125.60, 122.56, 
119.85, 119.67, 116.84, 116.56, 112.18, 89.99, 50.59, 50.14, 39.82, 35.64, 24.75, 20.09; LC-MS (ESI): m/z 499.1751 
[M +H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-(3-f luorophenyl)acetamide 
(13ac). Sticky white solid (0.047 g, 38.21%); 1H NMR (400 MHz, DMSO-d6): δ 10.38 (s, 1H), 9.70 (s, 1H), 9.27 
(s, 1H), 8.34 (s, 1H), 7.87 (d, J = 8.0Hz, 2H), 7.78 (d, J = 12.0Hz, 2H), 7.60 (d, J = 12.0Hz, 1H), 7.48 (d, J = 8.0Hz, 
2H), 7.34–7.27 (m, 4H), 6.85 (t, J = 8.0Hz, 1H), 6.25 (s, 1H), 3.60 (s, 2H), 3.13 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ 170.13, 163.72, 161.32, 161.17, 160.31 (d, 1JCF = 223Hz), 145.94, 141.42, 139.00, 132.43, 130.81, 
130.00, 129.92, 128.54, 120.87, 115.21, 115.19, 110.14 (d, 2JCF = 21Hz), 106.36 (d, 2JCF = 26Hz), 88.26, 44.44, 43.13; 
LC-MS (ESI): m/z 492.1703 [M +H]+.
2-(4-(6-(Methylamino)pyrimidin-4-yloxy)phenyl)-N-(4-fluorophenyl)acetamide (13ad). White solid (0.048 g, 
35.55%); m.p. 124–126 °C; 1H NMR (400 MHz, acetone-d6): δ 9.43 (s, 1H), 8.09 (s, 1H), 7.72–7.66 (m, 2H), 7.41 
(d, J = 8.0Hz, 2H), 7.10–7.04 (m, 4H), 6.47 (s, 1H), 5.83 (s, 1H), 3.71 (s, 2H), 2.90 (d, J = 8.0Hz, 3H); 13C NMR 
(100 MHz, acetone-d6): δ 168.78, 159.82 (d, 1JCF = 241Hz) 157.94, 152.27, 135.79, 132.45, 130.22, 121.37, 120.94, 
120.86, 120.77, 115.12 (d, 2JCF = 23Hz), 83.01, 42.97, 27.22; LC-MS (ESI): m/z 353.1776 [M +H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-cyclopropylacetamide (13ae). Yellow 
solid (0.036 g, 33.02%); m.p. 110–112 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.69 (s, 1H), 9.22 (s, 1H), 8.34 (s, 1H), 
8.08 (s, 1H), 7.86 (d, J = 12.0Hz, 2H), 7.78 (d, J = 12.0Hz, 2H), 7.43 (d, J = 8.0Hz, 2H), 7.17 (d, J = 8.0Hz, 2H), 6.23 
(s, 1H), 3.29 (s, 2H), 3.13 (s, 3H), 2.62–2.58 (m, 1H), 0.62–0.57 (m, 2H), 0.40–0.36 (m, 2H); 13C NMR (100 MHz, 
DMSO-d6): δ 171.92, 161.41, 160.50, 158.28, 146.14, 138.85, 132.62, 131.07, 129.90, 128.73, 121.07, 118.81, 88.32, 
44.64, 42.22, 23.00, 6.28; LC-MS (ESI): m/z 438.1555 [M + H]+.
2-(4-(6-(3-(Trifluoromethyl)phenylamino)pyrimidin-4-ylamino)phenyl)-N-cyclopropylacetamide (13af). Sticky 
pale yellow solid (0.040 g, 36.36%); 1H NMR (400 MHz, DMSO-d6): δ 9.46 (s, 1H), 9.14 (s, 1H), 8.29 (s, 1H), 
8.09–8.06 (m, 2H), 7.80 (d, J = 8.0Hz, 1H), 7.46 (t, J = 8.0Hz, 1H), 7.40 (d, J = 8.0Hz, 2H), 7.22 (d, J = 8.0Hz, 
1H), 7.14 (d, J = 8.0Hz, 2H), 6.13 (s, 1H), 3.26 (s, 2H), 2.61–2.54 (m, 1H), 0.59–0.55 (m, 2H), 0.37–0.33 (m, 2H); 
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13C NMR (100 MHz, DMSO-d6): δ 171.76, 161.10, 160.60, 158.12, 142.03, 138.79, 130.75, 130.18, 129.99, 129.69, 
123.36, 122.87, 120.79, 117.75, 115.31, 87.30, 42.05, 22.83, 6.11; LC-MS (ESI): m/z 428.1801 [M +H]+.
2-(4-(6-(2,3-Dihydrobenzo[b][1,4]dioxin-5-ylamino)pyrimidin-4-ylamino)phenyl)-N-cyclopropylacetamide 
(13ag). White solid (0.041 g, 37.27%); m.p. 234–226 °C; 1H NMR (400 MHz, acetone-d6): δ 8.21 (s, 1H), 8.19 (s, 
1H), 8.03 (s, 1H), 7.48 (dd, J = 4.0, 8.0Hz, 2H), 7.22 (d, J = 8.0Hz, 3H), 7.17–7.15 (m, 1H), 6.92–6.89 (m, 1H), 6.77 
(d, J = 8.0Hz, 1H), 6.10 (s, 1H), 4.27–4.23 (m, 4H), 3.37 (s, 2H), 2.73–2.66 (m, 1H), 0.65–0.60 (m, 2H), 0.44–0.40 
(m, 2H); 13C NMR (100 MHz, acetone-d6 + MeOD): δ 172.45, 161.38, 161.01, 157.88, 143.57, 139.71, 138.81, 
133.53, 130.12, 129.34, 120.39, 116.92, 114.47, 110.45, 84.60, 64.37, 64.13, 41.96, 22.27, 5.37; LC-MS (ESI): m/z 
418.1931 [M +H]+.
2-(4-(6-(4-Methylpiperazin-1-yl)pyrimidin-4-ylamino)phenyl)-N-cyclopropyl acetamide (13ah). Sticky colour-
less solid (0.042 g, 38.18%); 1H NMR (400 MHz, DMSO-d6): δ 8.95 (s, 1H), 8.13 (s, 1H), 8.04 (s, 1H), 7.42 (d, 
J = 8.0 Hz, 2H), 7.09 (d, J = 8.0HHz, 2H), 5.90 (s, 1H), 3.43 (t, J = 4.0Hz, 4H), 3.32 (s, 2H), 2.60–2.53 (m, 1H), 2.32 
(t, J = 4.0Hz, 4H), 2.17 (s, 3H), 0.58–0.54 (m, 2H), 036–0.34 (m, 2H); 13C NMR (100 MHz, DMSO-d6): δ 171.82, 
162.61, 161.42, 157.76, 139.31, 129.93, 129.56, 119.94, 84.26, 54.58, 46.20, 43.89, 42.03, 22.81, 6.10; LC-MS (ESI): 
m/z 367.2036 [M + H]+.
2-(4-(6-Morpholinopyrimidin-4-ylamino)phenyl)-N-cyclopropylacetamide (13ai). Yellow solid (0.038 g, 33.92%); 
m.p. 110–112 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.00 (s, 1H), 8.15 (s, 1H), 8.04 (s, 1H), 7.43 (d, J = 12.0Hz, 
2H), 7.10 (d, J = 8.0Hz, 2H), 5.90 (s, 1H), 3.63 (t, J = 4.0Hz, 4H), 3.40 (t, J = 4.0Hz, 4H), 3.23 (s, 2H), 2.60–2.53 
(m, 1H), 0.59–0.59 (m, 2H), 0.36–0.33 (m, 2H); 13C NMR (100 MHz, DMSO-d6): δ 171.82, 162.88, 161.43, 157.74, 
139.23, 130.03, 129.57, 120.01, 84.30, 66.20, 44.36, 42.02, 22.81, 6.10; LC-MS (ESI): m/z 354.3063 [M +H]+.
2-(4-(6-(Butylamino)pyrimidin-4-yloxy)phenyl)-N-(4-tert-butylthiazol-2-yl)acetamide (13aj). Colourless 
solid (0.055 g, 37.93%); m.p. 102–104 °C; 1H NMR (400 MHz, acetone-d6): δ 11.09 (s, 1H), 8.07 (s, 1H), 7.44 (d, 
J = 8.0Hz, 2H), 7.08 (d, J = 8.0Hz, 2H), 6.64 (s, 1H), 6.51 (s, 1H), 5.80 (s, 1H), 3.90 (s, 2H), 3.34 (s, 2H), 1.56 (t, 
J = 8.0Hz, 2H), 1.40–1.35 (m, 2H), 1.23 (s, 9H), 0.90 (t, J = 4.0Hz, 3H); 13C NMR (100 MHz, acetone-d6): δ 168.72, 
165.14, 160.68, 158.03, 157.10, 152.48, 131.64, 130.41, 130.21, 121.51, 104.37, 85.55, 41.53, 40.50, 34.07, 31.27, 
27.92, 19.78, 13.15; LC-MS (ESI): m/z 440.2009 [M +H]+.
N-(2,4-Dimethoxybenzyl)-2-(4-(6-(1-benzylpiperidin-4-ylamino)pyrimidin-4-yloxy)phenyl)acetamide 
(13ak). Yellow solid (0.048 g, 35.55%); m.p. 102–104 °C; 1H NMR (400 MHz, acetone-d6): δ 8.80 (s, 1H), 7.35–
7.27 (m, 6H), 7.23–7.20 (m, 1H), 7.10 (d, J = 8.0Hz, 1H), 7.02 (d, J = 8.0Hz, 2H), 6.50 (d, J = 4.0Hz, 1H), 6.46 (d, 
J = 8.0Hz, 1H), 6.43 (d, J = 4.0Hz, 1H), 6.41 (d, J = 4.0Hz, 1H), 5.77 (s, 1H), 4.28 (d, J = 4.0Hz, 2H), 3.77 (s, 3H), 
3.75 (s, 3H), 3.52 (s, 2H), 3.47 (s, 2H), 3.41–3.36 (m, 1H), 2.81 (s, 2H), 2.11 (d, J = 8.0Hz, 2H), 1.94 (d, J = 12.0Hz, 
2H), 1.57–1.49 (m, 2H); 13C NMR (100 MHz, acetone-d6): δ 169.71, 164.37, 160.40, 158.35, 158.13, 152.06, 139.09, 
133.22, 130.27, 129.46, 129.44, 128.71, 128.04, 126.75, 121.30, 119.18, 104.04, 98.06, 62.62, 54.81, 54.67, 52.17, 
42.11, 42.06, 37.90, 37.77, 31.98; LC-MS (ESI): m/z 568.1732 [M + H]+.
2-(4-(6-(4-(Methylsulfonyl)phenylamino)pyridin-2-ylamino)phenyl)-N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)
acetamide (18). Sticky white solid (0.040 g, 29.85%); 1H NMR (400 MHz, DMSO-d6): δ 9.98 (s, 1H), 9.39 (s, 1H), 
8.85 (s, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.67 (d, J = 8.0 Hz, 2H), 7.46–7.39 (m, 3H), 7.20 (d, J = 12.0Hz, 2H), 6.31 
(dd, J = 8.0, 12.0 Hz, 2H), 6.02 (s, 1H), 3.59 (s, 2H), 3.54 (s, 3H), 3.08 (s, 3H), 1.15 (s, 9H); 13C NMR (100 MHz, 
DMSO-d6): δ 169.78, 159.01, 154.97, 153.59, 146.88, 140.39, 139.28, 136.74, 130.86, 129.69, 128.41, 128.30, 119.60, 
117.40, 101.70, 101.38, 95.42, 44.50, 41.97, 35.69, 32.21, 30.75; LC-MS (ESI): m/z 533.2224 [M +H]+.
Synthesis of tert-butyl 4-(6-chloropyrimidin-4-ylamino)phenylcarbamate (20). To the mixture 
of tert-butyl 4-aminophenylcarbamate 19 (2.09 g, 10.06 mmol) and 4,6-dichloropyrimidine 6 (1 g, 6.71 mmol) in 
EtOH (20 mL) was added triethyl amine (1.17 g, 11.58 mmol) The reaction mixture was stirred at 80 °C for 12 h. 
After completion of reaction as indicate by TLC, the solvent was removed under reduced pressure. The crude 
product thus obtained was purified by silica gel (mesh 100–200) flash chromatography with hexanes/EtOAc (1:3) 
to afford 20 as a white solid (2.85 g, 89.06%); m.p. 155–157 °C; 1H NMR (400 MHz, CDCl3): δ 8.41 (s, 1H), 7.43 
(d, J = 8.0Hz, 3H), 7.22 (d, J = 8.0Hz, 2H), 6.66 (s, 1H), 6.58 (s, 1H), 1.53 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 
162.52, 160.45, 158.56, 152.71, 136.62, 131.71, 124.71, 119.73, 102.29, 80.91, 28.29; LC-MS (ESI): m/z 320.9424 
[M +H]+.
Synthesis of tert-butyl 4-(6-(4-(methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenylcar-
bamate (21). The 4-(methylsulfonyl)benzenamine 8a (0.802 g, 4.68 mmol) and Cs2CO3 (2.53 g, 7.78 mmol) 
were added to the solution of compound 20 (1 g, 3.12 mmol) in dioxane (4 ml). The reaction mixture was then 
degassed with argon. After completion of 5 minutes, Pd(PPh3)4 (0.108 g, 0.093 mmol) was added and the reaction 
mixture was allowed to stirr at 110 °C for 12 h. After completion of reaction as indicated by TLC, the solvent was 
removed under reduced pressure. The obtained residue was slowly basified with aqueous NaHCO3 and extracted 
with ethyl acetate (100 mL × 3). The organic layer was washed with aqueous NaHCO3 (100 mL × 3) followed by 
brine (100 mL × 3) solution. The obtained organic layer was dried over MgSO4, and solvent was evaporated to 
yield 21 as a yellow solid (0.950 g, 66.90%). m.p. 178–180 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.61 (s, 1H), 9.21 
(s, 1H), 9.08 (s, 1H), 8.28 (s, 1H), 7.83 (d, J = 8.0Hz, 2H), 7.74 (d, J = 12.0Hz, 2H), 7.38–7.32 (m, 4H), 6.12 (s, 
1H), 3.10 (s, 3H), 1.43 (s, 9H); 13C NMR (100 MHz,DMSO-d6): δ 161.42, 160.27, 158.10, 153.27, 146.01, 135.08, 
134.62, 132.36, 128.55, 121.92, 119.21, 118.56, 87.72, 79.25, 44.46, 28.58; LC-MS (ESI): m/z 455.9876 [M + H]+.
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Synthesis of N4-(4-aminophenyl)-N6-(4-(methylsulfonyl)phenyl)pyrimidine-4,6-diamine 
(22). Compound 21 (0.950 g, 1.0 mmol) was treated with 25% TFA/DCM at RT for 2 h, after which time the 
volatiles were removed in vacuo. The crude was diluted with EtOAc (100 mL), washed with saturated aq NaHCO3 
(100 mL × 3), and then with brine solution (100 mL × 3). The organic layer was dried over MgSO4 and concen-
trated in vacuo to provide the product 22 as yellow solid (0.736 g, 99.72%). m.p. 149–151 °C; 1H NMR (400 MHz, 
DMSO-d6): δ 9.51 (s, 1H), 8.66 (s, 1H), 8.20 (s, 1H), 7.81 (d, J = 8.0Hz, 2H), 7.72 (d, J = 8.0Hz, 2H), 6.99 (d, 
J = 8.0Hz, 2H), 6.54 (d, J = 8.0Hz, 2H), 5.93 (s, 1H), 4.92 (s, 2H), 3.08 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 
162.45, 160.25, 158.08, 146.18, 145.99, 132.11, 128.51, 128.21, 124.82, 118.38, 114.65, 86.34, 44.47; LC-MS (ESI): 
m/z 356.1468 [M +H]+.
General procedure for synthesis of 4,6-diaminopyrimidine series of compounds 24a-c. The 
reaction of compound 22 (0.100 g, 0.281 mmol) or its structural analogs with 3-tert-butyl-5-isocyanato-1-methyl-
1H-pyrazole (23) (0.057 g, 0.422 mmol), in presence of triethyl amine (0.098 g, 0.970 mmol), in DCM (2 mL) was 
stirred at 45 °C for 5 h. The completion of the reaction was monitored by TLC. After completion of the reaction, 
the organic layer was evaporated. The crude product was purified on silica gel column (mesh 100–200) using 
DCM: MeOH gradient (100: 0 to 70: 30 ratio of DCM: MeOH). The desired products 24a-c were isolated in 
moderate to good yields.
1-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-3-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)
urea (24a). Yellow solid (0.030 g, 20.0%); m.p. 238–240 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.66 (s, 1H), 9.15 
(s, 1H), 8.81 (s, 1H), 8.45 (s, 1H), 8.32 (s, 1H), 8.86 (d, J = 8.0Hz, 2H), 7.78 (d, J = 8.0Hz, 2H), 7.41 (s, 4H), 6.18 (s, 
1H), 6.03 (s, 1H), 3.59 (s, 3H), 3.13 (s, 3H), 1.20 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 161.38, 160.27, 158.92, 
158.09, 152.29, 146.02, 137.62, 134.74, 132.38, 130.93, 128.55, 121.94, 119.33, 118.58, 93.87, 87.83, 44.47, 35.36, 
32.23, 30.81; LC-MS (ESI): m/z 535.1774 [M +H]+.
1-(4-(6-(Methylamino)pyrimidin-4-ylamino)phenyl)-3-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea 
(24b). Yellow solid (0.020 g, 18.18%); m.p. 242–244 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.74 (s, 2H), 8.44 
(s, 1H), 7.99 (s, 1H), 7.35 (d, J = 8.0Hz, 2H), 7.30 (d, J = 8.0Hz, 2H), 6.67 (d, J = 4.0Hz, 1H), 5.99 (s, 1H), 5.60 (s, 
1H), 3.54 (s, 3H), 2.67 (d, J = 4.0Hz, 3H), 1.16 (s, 9H); 13C NMR (100 MHz, DMSO-d6): δ 163.54, 160.70, 159.02, 
157.85, 152.35, 137.64, 135.61, 134.11, 121,17, 119.40, 93.96, 85.39, 35.29, 32.20, 30.77, 27.86; LC-MS (ESI): m/z 
395.0813[M +H]+.
1-(4-(6-(4-(Methylsulfonyl)phenylamino)pyrimidin-4-ylamino)phenyl)-3-(5-tert-butylisoxazol-3-yl)urea 
(24c). Yellow solid (0.031 g, 21.23%); m.p. 245–247 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.67 (s, 1H), 9.44 (s, 
1H), 9.19 (s, 1H), 8.76 (s, 1H), 8.33 (s, 1H), 7.86 (d, J = 8.0Hz, 2H), 7.78 (d, J = 8.0Hz, 2H), 7.45 (d, J = 8.0Hz, 2H), 
7.39 (d, J = 12.0Hz, 2H), 6.48 (s, 1H), 6.18 (s, 1H), 3.13 (s, 3H), 1.28 (s, 9H); 13C NMR (100 MHz, DMSO-d6): 
δ 180.53, 161.31, 160.26, 158.85, 158.09, 151.79, 145.99, 135.29, 134.21, 132.41, 128.56, 121.76, 119.72, 118.60, 
92.83, 87.98, 44.46, 32.89, 28.78; LC-MS (ESI): m/z 522.1923 [M +H]+.
Biochemical Enzyme Inhibition Assay. Kinase activity was measured in a microfluidics assay that mon-
itors the separation of a phosphorylated product from substrate31,32. The assay was run using a 12-sipper chip 
on a Caliper EZ Reader II (PerkinElmer®, Walthman, USA) with separation buffer (100 mM HEPES, 10 mM 
EDTA, 0.015% Brij-35, 0.1% CR-3 [PerkinElmer®, Walthman, USA]). In 96-well polypropylene plates (Greiner, 
Frickenhausen, Germany) compound stocks (20 mM in DMSO) were diluted into kinase buffer (50 mM HEPES, 
0.075% Brij-35, 0.1% Tween 20, 2 mM DTT, 10 mM MgCl2, and 0.02% NaN3) in 12-point ½log dilutions (2 
mM–6.32 nM). After, 1 μL was transferred into a 384-well polypropylene assay plate (Greiner, Frickenhausen, 
Germany). The FLT3 enzyme (Invitrogen™, Grand Island, USA) was diluted in kinase buffer to a concentration 
of 2 nM and 5 µL of the enzyme mixture was transferred to the assay plate. The inhibitors/FLT3 enzyme were 
incubated for 60 minutes with minor shaking. A substrate mix was prepared containing ATP (Ambresco®, Solon, 
USA) and 5FAM tagged FLT3 peptide (peptide #22, 5′ FAM-EPLYWSFPA, PerkinElmer®, Walthman, USA) dis-
solved in kinase buffer, and 5 µL of the substrate mix was added to the assay plate. Running concentrations were 
as follows: ATP (190 µM), peptide (1.5 µM), compound 12-point ½log dilutions (0.2 mM–0.632 nM). For positive 
control, no inhibitor was added. For negative control, no enzyme was added. For running control, quizartinib was 
utilized. The plate was run until 10–20% conversion based on the positive control wells. The following separation 
conditions were utilized: upstream voltage −500V; downstream voltage, −1900V; chip pressure −0.8. Percent 
inhibition was measured for each well comparing starting peptide to phosphorylated product peaks relative to 
the baseline. Dose response curves, spanning the IC50 dose, were generated in GraphPad Prisim 6 and fit to an 
exponential one-phase decay line and IC50 values were obtained from the half-life value of the curve. IC50 values 
were generated in duplicate and error was calculated from the standard deviation between values.
Mechanism of Inhibition Procedure. Compound 13a was pre-incubated with the FLT3 kinase at 1, 3, 5, 
10, 20, 30, 50, and 90 minutes. After the pre-incubation, IC50 values at each incubation interval was determined 
according to the procedure outlined in section 4.3. In a separate experiment, compound 13a was pre-incubated 
with the FLT3 kinase for 60 minutes. After, IC50 values were determined at 5, 10, 20, 40, 80, and 160 µM ATP. To 
determine IC50 values at each concentration of ATP, the same procedure was followed as outlined in section S10.
Computational Modeling. Computational modeling31–33 studies were completed using AutoDock Vina33, 
AutoDock Tools, and Discovery Studio 3.5. Using AutoDock Tools, kinase crystal structures were prepared 
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as follows: 1) All hydrogens were added as ‘Polar Only’ 2) A grid box for the ATP binding site was created. 
Compounds to be computationally modeled were assigned appropriate rotatable bonds using AutoDock Tools. To 
computationally model the compounds, AutoDock Vina was employed. AutoDock Vina provides docking scores 
in terms of ΔG values. After the modeling study, kinase inhibitors docked in FLT3 were visualized and analyzed 
with Discovery Studio 3.5.
Cell Cultures. Stable BaF3 populations expressing activated FLT3 were generated by retroviral spinfec-
tion with the appropriate mutated plasmid followed by selection and growth factor withdrawal as previously 
described34. The BaF3 cell line was originally obtained from the laboratory of Charles Sawyers and has not been 
authenticated. MV411 and Molm14 cells were obtained from the laboratory of Scott Kogan and authenticated 
by Promega STR analysis in June 2013. All cell lines were mycoplasma-free. Cells were incubated with com-
pounds for 48 hours and proliferation was assessed using CellTiter-Glo (Promega; Madison, WI) according to the 
manufacturer’s recommendation on a SpectraMax M3 microplate reader using SpectraMax Software (Molecular 
Devices; Sunnyvale, CA). All cell viability data shown is reflective of experiments performed a minimum of three 
times.
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